Author details (full names, Emails, and
ORCIDs)
Emi Goto1,2, emi.goto@ompu.ac.jp,
https://orcid.org/0000-0001-9277-4449
Takeo Hata1, g7jndw@gmail.com,
https://orcid.org/0000-0001-5894-3552
Masami Nishihara1, masami.nishihara@ompu.ac.jp,
https://orcid.org/0000-0001-7976-2750
Masashi Neo1, neo@ompu.ac.jp,
https://orcid.org/0000-0001-9208-6419
Mitsuhiko Iwamoto3, mitsuhiko.iwamoto@ompu.ac.jp,
Kosei Kimura3, kosei.kimura@ompu.ac.jp,
https://orcid.org/0000-0002-0951-5890
Masahiro Goto4, masahiro.goto@ompu.ac.jp,
Yoshiyuki Rikitake2, rikitake@kobepharma-u.ac.jp,
https://orcid.org/0000-0001-7207-4656
Keywords: breast cancer, dexamethasone, human epidermal growth
factor receptor type 2, infusion-related reaction, trastuzumab